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A B S T R A C T
Personalized medicine is an emerging field in which clinical diagnostics information about a patient’s genotype or 
phenotype is used to optimize his/her pharmacotherapy. This article evaluates whether planar waveguide fluorescent 
sensors are suitable for determining such information from patient testing in point-of-care (POC) settings. The model 
system was Long QT Syndrome, a congenital disease associated with single nucleotide polymorphisms (SNPs) in genes 
encoding for cardiac ion channels. Three different SNP assay formats were examined: DNA/DNA hybridization, 
DNA/PNA hybridization (PNA: “peptide nucleic acid”), and single base extension (SBEX). Although DNA/DNA 
hybridization produced a strong intensity-time response for both wildtype and SNP analytes in a 5-min assay at 32°C, 
their hybridization rates differed by only 32.7%, which was insufficient for clinical decision-making. Much better 
differentiation of the two rates was observed at 53°C, where the wildtype’s hybridization rate was two-thirds of its 
maximum value, while that o f the SNP was essentially zero. Such all-or-nothing resolution would be adequate for 
clinical decision-making; however, the elevated temperature and precise temperature control would be hard to achieve 
in a POC setting. Results from DNA/PNA hybridization studies were more promising. Nearly 20-fold discrimination 
between wildtype and SNP hybridization rates was observed in a 5-min assay at 30°C, although the low ionic strength 
conditions required necessitated a de-salting step between sample preparation and SNP detection. SBEX was the most 
promising of the three, determining the absolute identity o f the suspected polymorphism in a 5-min assay at 40°C.
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1. IN T R O D U C T IO N
With the completion of the Human Genome Project1 in 2003 came the search for genetic polymorphisms within the 
genome. Such polymorphisms are responsible for diversity among individuals, but are also thought to be linked to 
predisposition to many common diseases2-4. Furthermore, genetic information about such polymorphisms can be used 
to assess the outcome of drug therapy (referred to as pharmacogenetics). For example, patient response to many drugs 
is highly individualized— plasma drug concentrations that are effective and well tolerated in one patient may cause 
adverse drug reactions in another. Often, such differences are linked to polymorphisms in the patient’s genetic makeup. 
Personalized medicine is an emerging field that makes use of a patient’s genetic information to optimize their therapy 
for both safety and efficacy.
Single nucleotide polymorphisms (SNPs) account for more than 90% o f all polymorphisms5. They occur every 100-300 
base pairs5; more than two-thirds are cytosine to thymine substitutions5. The human genome is thought to contain over
10 million SNPs6. To date, nearly 90% of these have been identified and deposited in public databases7,8. However, 
most o f these have little if any impact on human disease. In fact, direct linkages between polymorphisms and human 
disease have only been established for about 1,950 genes, so far9' 11. Interestingly, many of these genes contain multiple 
disease-linked polymorphisms— more than 49,000 have been reported in the 1,950 genes (average of about 25 
polymorphisms per gene), 57% of these are SNPs11. Needless to say, establishing new linkages between
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polymorphisms and human disease (referred to as direct candidate association) is a very active area o f research (see 
review by Suh and Vijg10). However, our work is more focused on personalized medicine— particularly developing 
rapid, inexpensive diagnostics assays for known SNPs, with the goal o f selecting the most efficacious pharmacotherapy 
for a given individual. We believe that the development of POC diagnostics testing methods for both SNPs and 
phenotypic markers will be an important factor in the development o f personalized medicine.
Presently, SNP testing is performed in reference or other clinical laboratories far from the point o f care. Such testing is 
time-consuming (turn-around time of several days) and expensive ($500-$2,500 per assay). Several different SNP 
testing methodologies are employed including electrophoresis-based techniques10,1213, microarrays14,15, real-time 
polymerase chain reaction16-18 (real-time PCR), and sequencing10. Except for real-time PCR, all o f these are too 
complex, slow and expensive for deployment in point-of-care (POC) environments. Real-time PCR is typically 
performed in low volume capillaries with fluorescence detection. Thus, it’s both rapid and sensitive, and good progress 
has been made in reducing the size and cost o f thermal cyclers. However, only a limited number of reactions (20-30) 
can be performed in parallel in a single machine. Still, we expect real-time PCR to migrate from clinical labs into POC 
environments over the next few years.
Over the past two decades, our laboratory has developed planar waveguide fluorescent biosensors for POC diagnostics 
applications. Our sensors are based on a patented injection-molded design that combines a 25 mm x 25 mm x 0.5 mm 
planar waveguide with an integral coupling lens19"23. The waveguide can be patterned with “capture” molecules such as 
antibodies or oligonucleotides. The integral lens enables precise optical alignment o f the removable sensor unit with a 
fixed light source and detection system. Injection molding decreases piece cost to a few dollars (or less with multi­
cavity injection) allowing waveguides to be used as one-shot, disposable sensors, which is important for clinical 
applications. Planar waveguide fluorescent biosensors offer the following attributes that make them ideal for rapid, POC 
diagnostics assays:
• Affinity assays (e.g., immunoassays, nucleic acid hybridization assays, drug-receptor assays, etc)
• Disposable sensor element (minimizes biosafety issues with human specimens)
• Point-of-care environments (e.g., physician’s office, out-patient clinics, emergency department, etc)
• High sensitivity (low picomolar range)
• Fast response time (typically 5 minutes at room temperature)
• No wash or reagent addition steps after initial sample injection (resulting in low complexity assays)
• Multi-channel detection (enabling multi-analyte assays and on-board calibration)
Initially, we developed clinical POC immunoassays for analytes such as cardiac troponin subunit I, chorionic 
gonadotrophin, creatine kinase isoform MB, and myoglobin24'27. More recently, we’ve developed POC assays for 
nucleic acids24,28'29, and biological warfare agents30. Our waveguide technology is potentially faster than all o f the SNP 
detection methodologies discussed previously, and less complex than electrophoresis-based methods, microarrays, and 
sequencing. It also potentially rivals microarray technology in terms of assay multiplicity. In fact, a planar waveguide 
patterned with capture molecules can be viewed as a microarray with integrated detection system.
In this report we examine the feasibility of using planar waveguide fluorescent biosensors for rapid SNP detection in 
POC environments. We chose Long QT Syndrome (LQTS) as a model congenital genetic disease because it has been 
linked to a series o f SNPs in genes encoding for cardiac ion channels31'34. Under physiological or emotional stress, 
affected individuals may develop a rare tachycardia referred to as torsade des pointes that results in syncope. 
Occasionally, this arrhythmia progresses into fatal ventricular fibrillation. These arrhythmias can be treated with an 
implantable defibrillator, or prophylactically with beta-blockers. However, affected individuals must first be diagnosed. 
Some (but not all) have a prolonged QT interval in their electrocardiograms. Thus, EKG is a useful preliminary 
screening procedure, but not necessarily conclusive because o f false negatives35. SNP screening can potentially provide 
a more conclusive diagnosis, as well as information about the optimum beta-blocker to employ36 (personalized 
medicine), but is not readily available because of high assay cost and the low frequency (1 in 5,000 to 1 in 7,000) of 
affected individuals. Thus, inexpensive SNP screening in LQTS is a significant unmet need.
We evaluated three different solid-phase molecular diagnostics assay formats that have been used for SNP detection — 
DNA-DNA hybridization, DNA-PNA hybridization (PNA is an abbreviation for “peptide nucleic acid”), and single base
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extension (SBEX). The two hybridization assays involve the immobilization o f a synthetic, single-stranded probe 
oligonucleotide (either DNA or PNA) that captures the analyte (also referred to as “target”) nucleic acid from solution. 
The analyte is often a gene or exon fragment isolated from patient DNA and amplified using polymerase chain reaction 
(PCR). After 20-30 PCR cycles, the product o f the PCR reaction (double-stranded DNA) is melted and snap cooled to 
give a single-stranded sample. For fluorescent assays, the PCR primers can be labeled with a fluorescent dye, 
conveniently giving fluorescently labeled analyte. Single base extension is a unique assay concept that involves both 
DNA hybridization and the enzyme-catalyzed incorporation of a dideoxynucleotide by DNA polymerase. Analyte 
DNA first hybridizes to the capture oligonucleotide, forming a DNA duplex that binds the polymerase. The sequence of 
the capture probe is designed so that the enzyme uses the suspected polymorphism in the analyte as its template for 
adding a complementary base to the 3’ end o f the capture probe. Fluorescently labeled dideoxynucleotide triphosphates 
are used as the substrate for the enzyme. The incorporated base can be identified by either wavelength or spatial 
resolution.
2. M E T H O D S
A succinct description of methods is given below. Please see our recent review article24 on planar waveguide 
fluorescent biosensors for a more complete description.
Biosensor. The biosensor assembly consisted of a planar waveguide sensor and a 3-channel flowcell. Planar 
waveguides w'ere injection molded from polystyrene using a single cavity tool by Opkor, Inc. (Rochester, NY). 
Flowcells consisted o f top and bottom plates machined from aluminum and anodized flat black. Three flow channels 
were milled into the top plate, each with small inlet and outlet ports and a 200-|xL volume. A Peltier device 
(thermoelectric heat pump) and heat sink was also attached to the top plate enabling temperature control o f the 
biosensor assembly over a range o f 10-70°C. Three windows were milled into the bottom plate to allow fluorescence 
imaging of each channel. The waveguide was inserted between the two plates and sealed against the top plate with a 
composite gasket (Teflon/silicone rubber) using mechanical pressure. The gasket’s low refractive index Teflon layer 
faced the waveguide and prevented the loss o f guided modes into the gasket. The more compliant silicone rubber layer 
was used to ensure a watertight seal against the metal top plate. The three barrels o f a computer-controlled syringe 
pump (Cavro Scientific Instruments, Sunnyvale, CA) were connected to the outlet ports o f the flowcell. When actuated, 
the pump created negative pressure within each channel that pulled samples into the flowcell via “sipper” tubes attached 
to each inlet port.
Instrumentation. Biosensor instrumentation consisted of a 12 mW, 635 nm semiconductor laser, beam-forming optics, a 
mounting pedestal for the biosensor assembly, and a CCD camera (Santa Barbara Instruments Group, Model ST-6 , 
Santa Barbara, CA). The laser was equipped with line-generating optics that produced a diverging beam with 
rectangular profile. The beam was expanded and collimated with beam-forming optics into a 20 mm x 1 mm sheet, 
which was then coupled with steering mirrors into the integral lens of the sensor. A computer-controlled, 
electromechanical shutter was placed between the laser and the beam-forming optics. It was closed between 
measurements to reduce photo bleaching. The CCD camera was equipped with a 55 mm f/2.8 macro lens (Nikon, 
Tokyo, Japan) that imaged the sensor’s three channels. A 670 nm band-pass interference filter (Orion, Santa Cruz, CA) 
inserted in front of the macro lens rejected scattered laser light. A Macintosh 7600 computer (Apple Computer, 
Cupertino, CA) with a PowerForce 280 MHz G3 accelerator card (PowerLogix, Austin, TX) acquired images from the 
CCD camera at 6 sec intervals. Data reduction consisted of dark count subtraction and summation (“binning”) o f the 
individual pixels in each channel. All instrument control, data acquisition, and data reduction operations were 
programmed using LabView version 4.0.1 (National Instruments Corp., Austin, TX). Specific control macros were 
written for each assay protocol. Typically, these collected data over a given assay period (5 or 16 min) and computed 
the mean reaction rate (and its standard error) for each channel using ordinary least squares.
SNP detection assays. Because the present report is a methods evaluation study, highly purified synthetic analyte 
oligonucleotides were used instead of PCR-amplified human DNA. The PCR amplification process is not without 
error, so the use of synthetic DNA ensured that our analyte oligonucleotides actually contained the nominal sequences. 
A model LQTS SNP was chosen for the methods evaluation study. In particular, we chose a known polymorphism
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occurring at position 760 in the KVLQT1 gene (encodes the alpha subunit of a cardiac muscle potassium channel), in 
which guanine is replaced by adenine (referred to as “G760A”). It’s a fairly common polymorphism and de-identified 
patient samples are available.
For DNA-DNA hybridization, the following probe and analyte oligonucleotides were synthesized, HPLC-purified, and 
mass spectrometry validated by the DNA/Peptide core facility at the University of Utah: 1) capture probe: 5 ’-biotin- 
ATGAAGACCACGGAGCCCAGG; 2) wildtype analyte: 5’-Cy5-CCTGGGCTCCGTGGTCTTCAT; and 3) G760A 
analyte: 5 ’-Cy5-CCTGGGCTCCATGGTCTTCAT. The wildtype analyte sequence corresponded to positions 750-770 
of the KVLQT1 gene. The same two analytes were used in DNA-PNA hybridization assays. The following PNA 
capture probe was purchased from Applied Biosystems (Foster City, CA): 5 ’-biotin-GAAGACCACGGAGCCCA. 
Different capture and analyte oligonucleotides were required for the SBEX assays: 1) capture probe: 5 ’-biotin- 
CCTGGCGGAGGATGAAGACCA; 2) wildtype analyte: 5 ’-TCCGTGGTCTTCATCCACCGCCAGGAGCT; and 3) 
G760A: 5’-TCCATGGTCTTCATCCACCGCCAGGAGCT. All three were synthesized, HPLC-purified and mass 
spectrometry validated at the DNA/Peptide core facility.
Capture oligonucleotides were immobilized to waveguides using a modular avidin/biotin approach. Clean waveguides 
were first coated with 150 nM neutravidin in PBS (phosphate buffered saline, pH 7.5) for 1 hr and washed twice in TE 
buffer (10 mM Tris, pH 7.4, with 1 mM ethylenediaminetetraacetic acid) to remove unadsorbed neutravidin. Capture 
oligonucleotide biotinylated at the 5’ end (50 nM in TE buffer) was allowed to react with the immobilized neutravidin 
for an additional hour. Unreacted oligonucleotide was then removed by washing twice in TE buffer. Finally, 
waveguides were post-coated with trehalose (0.1% w/v in TE buffer) and vacuum dried for several hours at room 
temperature. Trehalose protected the immobilized oligonucleotides, giving a shelf life of several months when stored 
desiccated at 4°C. All coating and post-coating steps were performed in gasketed coating trays. Coating gaskets were 
cut to the same pattern and dimensions as the flowcell gasket, so only the portion of the upper waveguide surface in 
contact with the three flow channels was coated with capture oligonucleotide.
The same general assay protocol was used for both types of hybridization assay. Analyte oligonucleotide was injected 
into the three flowcell channels and hybridization rate was monitored over time. Usually the same analyte 
concentration was injected into each channel, giving triplicate measurements o f the hybridization rate from a single 
biosensor assembly. The effects o f several different parameters (monovalent cation concentration, divalent cation 
concentration, and temperature) on hybridization rate were examined. These parameters were refined using a “design of 
experiments” 37 approach to give optimal discrimination between wildtype and G760A sequences.
A version of spatial resolution was used in our SBEX assay in which a given analyte was mixed independently with 
each of the four Cy5-labeled dideoxynucleotide triphosphates. Each mixture was then injected into separate channels of 
a biosensor assembly, and the base incorporation rate monitored over a 5 min period. Analysis of variance (ANOVA) 
and Dunnett’s post hoc test38 were used to analyte the results. Thermo sequenase was chosen as the DNA polymerase 
because fluorescent labeling of the dideoxynucleotides has little impact on its incorporation rate. Kits containing 
thermo sequenase as the four Cy5-ddNTPs were purchased from GE Healthcare (product no. 27-2682-01).
3. RESULTS AND DISCUSSION
3.1. DNA/DNA Hybridization SNP Assays
Figure 1 shows the reaction kinetics at 32°C for both the wildtype (Wt) and G760A analytes (100 pM) hybridizing to a 
capture oligonucleotide complementary to the wildtype analyte. These data were reported in our previous Analytical 
Biochemistry article28, and are included here as a reference point for the DNA/PNA hybridization and the single base 
extension assays. Both reactions took about 20 minutes to reach study-state, at which point the intensity of G760A was 
36.2% lower than that o f the Wt analyte. Thus, an end-point assay would take at least 20 minutes to run, with only 
marginal discrimination between perfectly matched and single-base mismatched species— clearly not adequate for POC 
SNP testing.
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Figure 1 -  Reaction kinetics for the Wt (open 
squares) and G760A (open circles) analytes 
hybridizing to an immobilized capture oligonuc­
leotide complementary to the Wt sequence (see 
Methods). The same reaction conditions were used 
for each analyte: 0.1 nM analyte; reaction 
temperature of 32'C; 10 mM Tris, pH 8.5, with 74 
mM NaCl, 800 mM KC1, 1 mM MgCl2, and 1 mM 
CaCl2. Fluorescence intensity measurements were 
taken every 20 seconds. Intensity measurements 
are given in arbitrary sensor units (SU). These 
data were previously reported by Tolley et a l2i, 
but are repeated here as a reference point for 
subsequent studies. Average hybridization rates 
(/?2 s) were determined by fitting Equation 1 to data 
obtained during the initial 5 minutes of the reaction 
(see text). Curve fits are shown as the solid line 
through the first 20 points of each data set.
Time (min)
Because our biosensor system has a 5-min assay time specification, we also compared hybridization rates obtained from 
the first 5 minutes o f each data set. Rates were evaluated at the midpoint (2.5 min) of each 5-min data set using 
Equation 1:
it tor'll' i
! _ eW11 = !o + Rt,
*tech
(i)
where /, is intensity at time t, lo is initial intensity, Rt . is hybridization rate evaluated at time /,, and kteci, is a technical
(empirical) rate constant. Rate values o f 4.02±0.03 x 105 SU/min and 2.71±0.02 x 105 SU/min were determined for the 
wildtype and G760A analytes, respectively by non-linear curve fitting by ordinary least squares. Curve-fits are shown 
as solid lines in Figure 1. Thus, the G760A analyte hybridizes more slowly (32.7%) than the Wt analyte. Although the 
rate-based method reduces assay time, discrimination is a bit worse that reported above for the end-point assay.
The situation would be more even complex in an actual clinical assay because the patients will have two alleles. 
Individuals with a Wt genotype will have two Wt alleles, both of which would hybridize at the maximum rate (which 
we’ll define as 100%). Heterozygous individuals would have one Wt and one G760A allele. The observed rate would 
then be the weighted average of the Wt rate and the G760A rate, or 83.6% of the Wt rate. Exceedingly rare autosomal 
recessive individuals would have two G760A alleles, both of which would hybridize at the G760A rate, which is 67.3% 
of the Wt rate. The most common clinical decision would be between Wt and heterozygous individuals, but their 
observed hybridization rates would only differ by 16.4%. Such a decision point would require very good assay 
precision (coefficient o f variation (CV) of < 5%), and very tight control on assay conditions such as analyte 
concentration, temperature, and cation concentrations. Such tight control would be challenging to achieve in an 
inexpensive POC assay system. Thus, we investigated whether better discrimination between Wt and G760A could be 
achieved at higher temperatures.
Figure 2 shows the results o f a temperature ramping experiment performed between 51°C and 55°C. Hybridization 
rates for both Wt and G760A analytes were measured at five different temperatures within the above range. Each data 
set was normalized by the maximum observed rate within the range. These experiments showed that the melting 
temperature (Tm) o f the G760A analyte was 1.1°C lower than that o f the Wt analyte. The data also showed that 53°C 
was the ideal temperature for distinguishing these two analytes. At that temperature, the hybridization rate of the Wt 
analyte was 66.1% of its maximum value, while that o f the G760A analyte was essentially zero. Although this 
discrimination is adequate for a clinical decision point, maintaining a 53°C assay temperature with 0.1 °C (or better) 
precision would be very challenging in a rapid, POC assay system. Furthermore, the ideal reaction temperature (i.e., 
temperature giving maximum discrimination between SNP and Wt) is expected to vary with different SNPs. This 
would be problem in screening for multiple SNPs with a single planar waveguide sensor (long term goal o f this project)
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Figure 2 -  Temperature ramping study using 
DNA/DNA hybridization assay. Hybridization 
assays were performed at 5 different reaction 
temperatures over a range of 51 -55°C for both Wt 
and G760A analytes. A Peltier device attached to 
the flowcell top plate controlled temperature.
Assay temperature was monitored with a 
thermister inserted in the top plate, immediately 
above the waveguide. Temperature was 
equilibrated for 5-10 minutes before performing 
assays. Assay conditions were identical to those 
given in Figure 1 , except for the elevated 
temperatures and the 5-min data collection period 
Hybridization rates were evaluated at the 2.5-min 
point using Equation 1. Data for a given analyte 
were normalized to its maximum hybridization rate 
observed over the temperature range. Melting 
temperature (Tm) was operatively defined as the 
temperature at which hybridization rate was 
reduced to 50% of its maximum value. Using this 
definition, the Tm of the Wt analyte was 1.1 °C 
higher than that of the G760A analyte (denoted by 
the horizontal line with double arrows). The 
50 51 52 53 54 55 56 vertical dashed line shows the ideal assay
temperature (see text).
Temperature (°C)
because no single temperature would give ideal discrimination for all hybridization reactions. Temperature could be 
ramped (as was done in collecting the data shown in Figure 2), but assay times would be much longer because a 5-10 
minute equilibration period is required after ramping to each new temperature, followed by the 5-min assay period, 
giving a total assay time of 50-75 minutes.
3.2. DNA/PNA Hybridization SNP Assays
Peptide nucleic acid (PNA) is a hybrid, synthetic polymer consisting of nucleoside bases covalently attached to a 
polypeptide backbone. It has some benefits over DNA as a capture strand in hybridization assays including: 1) reduced 
counter ion requirements; 2) faster hybridization rates; 3) greater duplex stability; and 4) better resistance to enzymatic 
digestion.39,40 These benefits are potentially advantageous for planar waveguide biosensors as well, so we investigated 
PNA as a capture molecule in the hybridization assay described above. The analyte oligonucleotides (Wt & G760A) 
were the same, but the PNA capture probe was a 17-mer (sequence described in Methods) instead of the 21-mer DNA 
capture probe used above (17-mers were the longest PNA probes available commercially at the time these assays were 
performed). Hybridization assays were performed in triplicate for 5 min at 30°C in 10 mM Tris buffer, pH 8.4. 
Different concentrations of both monovalent (Na+, K+) and divalent cations (Ca2+, Mg2+) were added combinatorially to 
this buffer using a “design o f experiments” approach37. Sixteen different combinations of cation concentrations were 
examined. The best discrimination between Wt and G760A analytes was observed at relatively low concentrations of 
both monovalent and diavalent cations (0.24 mM NaCl, 0.24 mM KC1, 0.2 mM CaCl2, 0.2 mM MgCl2), as shown in 
Figure 3. Under these conditions, the hybridization rate o f G760A was 19-fold lower than that o f the Wt analyte, which 
is a 94.7% decrease relative to Wt. The figure also shows a clear trend for better discrimination with decreasing NaCl 
and KC1 concentration. Nevertheless, the hybridization rate o f both analytes was markedly reduced in the absence of 
cations (data not shown). Although some additional gains in discrimination may be achieved by going to even lower 
cation concentrations, there is a trade off—namely, PCR is typically run in a buffer containing 10 mM Tris, pH 8.3, 
with 50 mM KC1 and 1.5 mM MgCl2. Thus, amplified analyte DNA from PCR would have to be desalted before being 
detected by DNA/PNA hybridization. Although not a problem in clinical laboratory settings, the desalting step would 
add complexity in a POC environment. Nevertheless, if this challenge can be overcome by microfluidic or other lab-on- 
a-chip approaches, the nearly 20-fold attenuation of the single-base mismatched species relative to the perfectly













Figure 3 -  Potassium and sodium cation effects on 
the DNA/PNA hybridization rates of Wt analyte 
(gray) and G760A analyte (white) at low divalent 
cation concentration. DNA/PNA hybridization 
assays were performed for 5 minutes at 30"C in 10 
raWTris buffer, pH 8.4 containing 0.2 mM MgCl2 
and 0.2 mMCaCl2, and the sodium and potassium 
concentrations shown in the figure. Analyte 
concentration was 1 nM in all cases. Each assay 
was performed in triplicate. Average hybridization 
rates were determined by fitting Equation 1 to 
intensity versus time data as described above for 
the DNA/DNA hybridization assay.
0.24 mM potass'urr'
matched species has the intrinsic resolution to detect SNPs in a hybridization-based method at near-ambient 
temperatures.
3.3. Single Base Extension SNP Assays
Because both types of hybridization assays had some shortcomings for POC testing, we investigated single base 
extension as a method for rapid SNP detection. SBEX is more accurate at detecting single base changes than 
hybridization assays because it exploits the intrinsic base incorporation fidelity o f the DNA polymerase enzyme. Figure 
4 shows single base extension reactions for all pair wise combinations of the Wt and G760A analytes with the four 
different dideoxynucleotide triphosphates (ddNTPs). A sham reaction containing buffer and DNA polymerase, but 
without analyte or ddNTP was run as a control blank. All reactions were run for 5 minutes at 40°C. For the Wt analyte, 
analysis of variance (ANOVA) followed by Dunnett’s38 post hoc test showed that only the incorporation rate of the 
complementary cytosine dideoxynucleotide triphosphate (ddCTP) was significantly higher (P < 0.001) than that o f the 
blank. Similarly for the G760A analyte, only incorporation of its complemenary thymidine dideoxynucleotide 
triphosphate (ddTTP) was statistically significant (P < 0.001). Dunnett’s test also showed that all reactions 
incorporating non-complementary bases were statistically indistinguishable (P > 0.99) from the control blank. Thus, 












Figure 4 -  Single base extension assays for the Wt 
and G760A analytes. All assays were performed 
with 0.1 nM analyte concentration for 5 min at 
40'C in 10 mM Tris buffer (pH 8.5) with 10 mM 
MgCl2 and 2 units of Thermo Sequenase. The 
following concentrations of Cy5-labeled 
dideoxynucleotide were used to compensate for 
reported41 differences in reactivity: 4.0 nM of 
ddTTP, 4.9 nM of ddGTP, 2.0 nM ddCTP, and 2.5 
nM ddATP. The intensity-time response of the 
sensor was linear over the assay period, so reaction 
rates were determined from the slopes of intensity 
vs. time curves using linear regression. Reaction 
rate values obtained for each analyte were 
compared to the blank rate using ANOVA and 
Dunnett’s38 post hoc test. Asterisks denote 
statistically significant (P < 0.001) rate values.
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4. CONCLUSIONS
All three assays were able to detect SNPs at 1 nM analyte concentrations or lower, though the two hybridization assays 
required more stringent conditions than the single base extension assay. For example, the DNA/DNA hybridization 
assay exhibited best discrimination between matched and mis-matched sequences at temperatures above the Tm o f the 
SNP, but below that o f the Wt. This was a fairly strong condition for the sequences examined herein whose melting 
temperatures were both above 50°C and only differed by 1.1 °C. More generally, it limits the practical application of 
DNA/DNA hybridization for SNP detection in rapid, POC assays. In contrast, the DNA/PNA hybridization assay 
exhibited excellent discrimination (19-fold) in a 5-min assay at only 30°C; however, such discrimination was only 
achievable with sub-millimolar concentrations of monvalent and divalent cations in the reaction mixture. This 
limitation has the practical consequence that samples prepared by polymerase chain reaction would have to be desalted 
before being assayed, which would complicate the fluidics o f  a POC SNP detection system. Single base extension gave 
the best results o f the three assays— nearly absolute discrimination in a 5-min assay at 40°C. It is also the most readily 
adaptable o f the three assay formats to multiple SNP assays on a single sensor chip. Shortcomings include a 40°C 
reaction temperature to achieve our 5 min assay specification and $5/assay reagent costs. The former should be 
obtainable in a POC instrument system, but may preclude a battery-powered handheld instrument.
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